Advaxis (NASDAQ: ADXS) is a late -stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.
Looking for a particular Advaxis, Inc. employee's phone or email?
The Advaxis, Inc. annual revenue was $15 million in 2026.
Frances Gavigan is the Associate Director, Clinical Quality Assurance of Advaxis, Inc..
5 people are employed at Advaxis, Inc..
Advaxis, Inc. is based in Princeton, New Jersey.
The NAICS codes for Advaxis, Inc. are [325413, 32541, 32, 325, 3254].
The SIC codes for Advaxis, Inc. are [28, 283].